



Advanced Control Formulary®
Change Summary Report
Effective 10-01-2022

This report highlights all changes (additions, deletions, and removals) to the CVS Caremark® Advanced Control Formulary.

ADDITIONS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			
Eliquis (apixaban) oral tablet, oral starter pack kit	Hematologic/ Anticoagulants, Oral	Eliquis is indicated for: <ul style="list-style-type: none">• Reduction in risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.• Prophylaxis of deep vein thrombosis (DVT) in patients who have undergone hip or knee replacement surgery.• Treatment of DVT and pulmonary embolism (PE).• Reduction in risk of recurrent DVT and PE following initial therapy.	To provide an additional option for DVT and PE.
Restasis (cyclosporine ophthalmic emulsion 0.05%) ophthalmic emulsion	Topical/ Ophthalmic/ Dry Eye Disease	Restasis ophthalmic emulsion is indicated to increase tear production in patients whose tear production is presumed to be suppressed due to ocular inflammation associated with keratoconjunctivitis sicca.	To provide an additional option for dry eye disease.
Generic Agents:			
glucagon, human recombinant subcutaneous/	Endocrine and Metabolic/ Glucose Elevating Agents	Glucagon, human recombinant, is indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes.	To provide an additional option for treatment of severe hypoglycemia.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
intramuscular/ intravenous solution for injection			

REMOVALS:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Generic Agents:			
betamethasone dipropionate ointment 0.05% topical ointment	Topical/ Dermatology/ Corticosteroids/ High Potency	Betamethasone dipropionate ointment is indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 13 years of age or older.	Availability of additional high potency topical corticosteroids. Preferred options on the Advanced Control Formulary include desoximetasone (except desoximetasone ointment 0.05%), fluocinonide (except fluocinonide cream 0.1%), and Bryhali (halobetasol propionate lotion 0.01%).
clobetasol emollient foam topical emollient foam	Topical/ Dermatology/ Corticosteroids/ Very High Potency	Clobetasol propionate topical emollient foam is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older.	Availability of additional very high potency topical corticosteroids. Preferred options on the Advanced Control Formulary include clobetasol cream, clobetasol foam (except clobetasol emollient foam), clobetasol gel, clobetasol lotion, clobetasol ointment, halobetasol cream, and halobetasol ointment.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary®
 Change Summary Report
 Effective 10-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
doxycycline hyclate tablet 50 mg oral tablet	Anti-Infectives/ Antibacterials/ Tetracyclines	Doxycycline hyclate 50 mg is indicated for: <ul style="list-style-type: none"> • Rickettsial infections. • Sexually transmitted infections. • Respiratory tract infections. • Specific bacterial infections. • Ophthalmic infections. • Anthrax, including inhalational anthrax (post-exposure). • Alternative treatment for selected infections when penicillin is contraindicated. • Adjunctive therapy in acute intestinal amebiasis and severe acne. • Prophylaxis of malaria. 	Availability of additional generic tetracycline options. Preferred options on the Advanced Control Formulary include doxycycline hyclate capsule, doxycycline hyclate tablet (except doxycycline hyclate tablet 50 mg, 75 mg, 150 mg), minocycline, and tetracycline.
lansoprazole delayed-rel orally-disintegrating tablet oral delayed-release disintegrating tablet	Gastrointestinal/ Proton Pump Inhibitors	Lansoprazole delayed-rel is indicated for: <ul style="list-style-type: none"> • Short-term treatment of active duodenal ulcer. • <i>H. Pylori</i> eradication to reduce the risk of duodenal ulcer recurrence in combination with amoxicillin plus clarithromycin. • Maintenance of healed duodenal ulcers. • Short-term treatment of active benign gastric ulcer. • Healing of non-steroidal anti-inflammatory drugs (NSAID)-associated gastric ulcer. 	Availability of additional generic proton pump inhibitors. Preferred options on the Advanced Control Formulary include esomeprazole delayed-rel, lansoprazole delayed-rel capsule, omeprazole delayed-rel, and pantoprazole delayed-rel tablet.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®
 Change Summary Report
 Effective 10-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
		<ul style="list-style-type: none"> Risk reduction of NSAID-associated gastric ulcer. Short-term treatment of symptomatic gastroesophageal reflux disease (GERD) and erosive esophagitis (EE). Maintenance of healing of EE. Pathological hypersecretory conditions including Zollinger-Ellison Syndrome (ZES). 	
Tovet (clobetasol emollient foam) topical emollient foam	Topical/ Dermatology/ Corticosteroids/ Very High Potency	Tovet is indicated for the treatment of inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses in patients 12 years and older.	<p>Availability of additional very high potency topical corticosteroids.</p> <p>Preferred options on the Advanced Control Formulary include clobetasol cream, clobetasol foam (except clobetasol emollient foam), clobetasol gel, clobetasol lotion, clobetasol ointment, halobetasol cream, and halobetasol ointment.</p>

OTHER:

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Brand Agents:			

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.

Advanced Control Formulary® Change Summary Report Effective 10-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
Rinvoq (upadacitinib) oral extended-release tablet	Immunologic Agents/ Autoimmune Agents (Self-Administered)	Rinvoq is indicated for the treatment of: <ul style="list-style-type: none"> • Adults with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to one or more tumor necrosis factor (TNF) blockers. • Adults with active psoriatic arthritis who have had an inadequate response or intolerance to one or more TNF blockers. • Adults and pediatric patients 12 years of age and older with refractory, moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies are inadvisable. • Adults with moderately to severely active ulcerative colitis who have had an inadequate response or intolerance to one or more TNF blockers. • Adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more TNF blockers. 	Now preferred for ankylosing spondylitis. Note: Rinvoq remains preferred for: <ul style="list-style-type: none"> • Atopic dermatitis • Psoriatic arthritis • Rheumatoid arthritis • Ulcerative colitis (after failure of Humira [adalimumab])
Stelara Subcutaneous (ustekinumab)	Immunologic Agents/ Autoimmune Agents	Stelara Subcutaneous is indicated for the treatment of:	Now first line for ulcerative colitis. No longer requires a prior failure of Humira (adalimumab).

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.



Advanced Control Formulary®
 Change Summary Report
 Effective 10-01-2022

Product	Therapeutic Category/ Subcategory	Indication	Options/Comments
subcutaneous solution for injection	(Self-Administered)/ Ulcerative Colitis	<ul style="list-style-type: none"> Moderate to severe plaque psoriasis in patients 6 years or older. Adult patients with active psoriatic arthritis. Moderately to severely active Crohn's disease in adults. Moderately to severely active ulcerative colitis in adults. 	Note: Stelara Subcutaneous remains preferred for Crohn's disease, psoriasis, and psoriatic arthritis.
Zeposia (ozanimod) oral capsule, oral starter pack, oral starter kit	Immunologic Agents/ Autoimmune Agents (Self-Administered)/ Ulcerative Colitis	Zeposia is indicated for the treatment of: <ul style="list-style-type: none"> Moderately to severely active ulcerative colitis in adults. Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. 	Now first line for ulcerative colitis. No longer requires a prior failure of Humira (adalimumab). Note: Zeposia remains preferred for multiple sclerosis.

This document contains references to brand-name prescription drugs that are trademarks or registered trademarks of pharmaceutical manufacturers not affiliated with CVS Caremark. The information contained in this document is proprietary. The information may not be copied in whole or in part without written permission.

©2022 CVS Health and/or one of its affiliates. All rights reserved.